Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

AbbVie touts Qulipta chronic migraine win as Biohaven duel heats up
Fierce Pharma
Thu, 03/10/22 - 10:22 pm
Tags:
AbbVie, Biohaven, migraines, Qulipta, Nurtec
AbbVie, Alvotech settle Humira patent and trade secrets disputes, teeing up another biosim rollout next year
Fierce Pharma
Wed, 03/9/22 - 10:46 am
Tags:
Alvotech, AbbVie, Humira, biosimilars, legals, patents, trade secrets
AbbVie closes U.S. pension plan to new hires
Pensions and Investments
Thu, 03/3/22 - 10:36 am
Tags:
AbbVie, pensions, employee benefits
Rare disease and neurology take outs tick higher
EP Vantage
Wed, 03/2/22 - 10:03 am
Tags:
M&A, AbbVie, AstraZeneca, Bristol Myers Squibb, JNJ, Gilead Sciences, Jazz Pharmaceuticals, Merck, Pfizer, Sanofi, rare disease, neurology
AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer's and depression prospect
Fierce Biotech
Tue, 03/1/22 - 10:42 am
Tags:
AbbVie, M&A, Neuroscience, Syndesi Therapeutics, UCB Pharma, Alzheimer's disease, depression
AbbVie files sNDA to FDA for chronic graft versus host disease therapy
Pharmaceutical Business Review
Tue, 03/1/22 - 10:24 am
Tags:
AbbVie, Imbruvica, graft vs host disease, FDA
AbbVie ditches fibrosis program it paid Morphic $20M for in 2020
Fierce Biotech
Fri, 02/25/22 - 09:56 am
Tags:
AbbVie, Morphic Therapeutic, idiopathic pulmonary fibrosis
Teva, Endo and more back on the hook in San Francisco opioid trial
Fierce Pharma
Thu, 02/24/22 - 11:00 pm
Tags:
opioids, San Francisco, Teva Pharmaceutical, Endo International, AbbVie, Allergan
AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?
Endpoints
Wed, 02/23/22 - 10:24 pm
Tags:
AbbVie, Vraylar, Allergan, major depressive disorder, FDA
AbbVie submits sNDA to FDA for major depressive disorder therapy
Pharmaceutical Business Review
Wed, 02/23/22 - 10:18 am
Tags:
AbbVie, FDA, cariprazine, major depressive disorder
AbbVie Snags FDA Approval for Another Indication. Will It Become Another Blockbuster?
Motley Fool
Fri, 02/18/22 - 10:30 am
Tags:
AbbVie, Skyrizi, FDA, psoriatic arthritis
Organon CEO pins high hopes on upcoming Humira biosimilar launch
Fierce Pharma
Thu, 02/17/22 - 11:18 pm
Tags:
Organon, biosimilar, Humira, drug launches, AbbVie
AbbVie runs first Qulipta TV ad spots as it focuses on what you ‘can control inside’
Fierce Pharma
Fri, 02/11/22 - 11:46 am
Tags:
AbbVie, pharma marketing, migraines, Qulipta, television ads, DTC ads
AbbVie’s Qulipta gains ground with docs for migraine prevention, as pharma looks to pressure Biohaven’s Nurtec
Fierce Pharma
Thu, 02/10/22 - 08:02 pm
Tags:
AbbVie, Biohaven, migraines, Qulipta, Nurtec ODT
AbbVie's blockbuster eye drug Restasis under threat as FDA approves Viatris' copycat
Fierce Pharma
Wed, 02/2/22 - 11:50 pm
Tags:
AbbVie, earnings, Restasis, FDA, generics
AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
Endpoints
Wed, 02/2/22 - 11:46 pm
Tags:
AbbVie, earnings, Rick Gonzalez, Skyrizi, Rinvoq
AbbVie notches reprieve in antitrust case involving blood pressure med snagged in $63B Allergan megamerger
Fierce Pharma
Wed, 01/26/22 - 11:00 am
Tags:
AbbVie, antitrust, Bystolic, generics, Allergan
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
Yahoo/Zacks.com
Mon, 01/24/22 - 11:30 pm
Tags:
AbbVie, Skyrizi, FDA, psoriatic arthritis
What This FDA News Could Mean for AbbVie's Stock
Motley Fool
Mon, 01/24/22 - 10:10 am
Tags:
AbbVie, Rinvoq, FDA
3 Clinical Trials to Watch in the First Half of 2022
Motley Fool
Sat, 01/22/22 - 02:20 pm
Tags:
clinical trials, Pfizer, Arena Pharmaceuticals, etrasimod, Roche, Alzheimer's disease, gantenerumab, AbbVie, cystic fibrosis

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.